Palisade Bio shares rise 14.44% intraday after Maxim raises price target to $8 from $2 with Buy rating.

Monday, Nov 17, 2025 9:35 am ET1min read
Palisade Bio surged 14.44% during intraday trading after Maxim raised its price target to $8 from $2 and maintained a Buy rating, citing lower risk. The upgraded target reflects increased confidence in the firm’s prospects, likely driving investor buying.

Comments



Add a public comment...
No comments

No comments yet